C. Murphy

Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting

C. Slingluff, W. Grosh, G. Petroni, 2007, Clinical Cancer Research.

A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer

C. Slingluff, W. Olson, G. Petroni, 2008, Journal of immunotherapy.

Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate‐specific antigen‐producing tumors in athymic and SCID/bg mice using LNCaP and lineage‐derived metastatic sublines

C. Kao, G. Balian, R. Sikes, 1998, International journal of cancer.

Immunogenicity for CD8+ and CD4+ T Cells of 2 Formulations of an Incomplete Freund's Adjuvant for Multipeptide Melanoma Vaccines

M. Ross, J. Kirkwood, C. Slingluff, 2010, Journal of immunotherapy.

Multipeptide Vaccine for Melanoma ISA-51 Adjuvant and Administered as Part of Colony-Stimulating Factor and Montanide with Granulocyte-Macrophage Peptides Are Immunogenic When Combined MAGE-A 1-, MAGE-A 10-, and gp 100-Derived

E. Bissonette, C. Slingluff, W. Grosh, 2005 .

MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab

Kevin M. D'Auria, K. M. D'Auria, Anindya Dutta, 2013, Journal of Translational Medicine.

MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma1

Gina R Petroni, E. Bissonette, C. Slingluff, 2005, The Journal of Immunology.

VEGFR‐2 expression in human melanoma: Revised assessment

C. Slingluff, D. Brautigan, J. Patterson, 2011, International journal of cancer.